BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 20, 2025
Home » Authors » Michael Fitzhugh

Michael Fitzhugh

Articles

ARTICLES

US report citing 'atypical' Aduhelm approval calls on FDA, drugmakers to do better

Dec. 30, 2022
By Michael Fitzhugh
Citing an "atypical FDA review process and corporate greed" ahead of the controversial approval of Biogen Inc.'s Aduhelm (aducanumab), Energy and Commerce Committee Chairman Frank Pallone (D-N.J.) called for "corrective actions" at the agency to "re-earn the trust of the American people." Pallone's comments prefaced a report drawn from 18 months of investigation around the regulatory review and approval process for the Alzheimer's disease drug, as well as Biogen’s pricing strategy.
Read More

Post-dose escalation SAEs vex Magenta in phase I/II trial

Dec. 20, 2022
By Michael Fitzhugh
Magenta Therapeutics Inc., the developer of an antibody-drug conjugate intended to help prep certain relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome patients for stem cell transplant or gene therapy, has stopped dosing the drug in part of an ongoing trial after observing two cases of serious adverse events (SAEs) possibly related to the candidate.
Read More

Gossamer shares sink on phase II PAH data

Dec. 6, 2022
By Michael Fitzhugh
Gossamer Bio Inc. shares (NASDAQ:GOSS) fell 74.6% to $2.36 Dec. 6 after the disclosure of phase II results that, while meeting the study's primary endpoint of reducing pulmonary vascular resistance vs. placebo, failed to show the company's pulmonary arterial hypertension (PAH) candidate, seralutinib, holding its own against the performance of Merck & Co. Inc.'s PAH candidate, sotatercept, in separate PAH studies.
Read More

Out of SORTs: Theratechnologies puts trial enrollment on pause as cancer candidate falls short

Dec. 2, 2022
By Michael Fitzhugh
Theratechnologies Inc. paused enrollment of a phase I trial testing TH-1902, its lead peptide-drug conjugate for sortilin-expressing cancers, after finding efficacy "not convincing enough" nor outweighing adverse events in some participants, an undisclosed number of which experienced neuropathy and eye toxicity, the company said.
Read More
Syringe and ampoules

Researchers establish proof of concept for germline-targeting HIV vaccine

Dec. 1, 2022
By Michael Fitzhugh
A diverse group of government and academic researchers, marking World AIDS Day 2022, have published details of an investigational vaccine they said safely induced broadly neutralizing antibody-precursors against HIV in nearly all participants in a small phase I trial.
Read More
Chess board and hybrid pawn

Horizon sees interest from trio of big pharma suitors

Nov. 30, 2022
By Michael Fitzhugh
Horizon Therapeutics plc shares (NASDAQ:HZNP) jumped 27.3% to $100.29 after the company disclosed being in "highly preliminary" discussions about takeover interests expressed by Amgen Inc., Janssen Global Services LLC and Sanofi SA. The companies have until Jan. 10, 2023, to report whether they intend to make an offer or not.
Read More

Cajal raises $96M to accelerate neurodegeneration drug discovery

Nov. 29, 2022
By Michael Fitzhugh
Cajal Neuroscience Inc., a startup seeking new targets to use in medicines for neurodegeneration, has launched with the completion of a $96 million series A financing led by The Column Group and Lux Capital. The company, inspired by the pioneering work of Santiago Ramón y Cajal, is focused on the "mechanistic, spatial and temporal complexity of neurodegeneration" to determine "how, where and when different mechanisms contribute to disease."
Read More
Lung cancer illustration

Affirming advisers, FDA rejects Spectrum lung cancer drug with CRL

Nov. 28, 2022
By Michael Fitzhugh
Spectrum Pharmaceuticals Inc. president and CEO Tom Riga said the company would "immediately deprioritize" its poziotinib program after the U.S. FDA issued a complete response letter (CRL) suggesting the company would have to generate new clinical data prior to potential approval.
Read More

Northwest glioblastoma therapy extends OS, ‘long tail' survival, in phase III trial

Nov. 18, 2022
By Michael Fitzhugh
An investigational dendritic cell vaccine from Northwest Biotherapeutics Inc., administered with standard of care, extended both median overall survival (OS) and "the ‘long tail' of the survival curve" vs. matched external controls in newly diagnosed and recurrent glioblastoma multiforme brain cancer patients, according to results published Nov. 17 in JAMA Oncology.
Read More
Antibodies attacking cancer cell

Regeneron taps Cytomx tech in $2.03B bispecifics deal

Nov. 17, 2022
By Michael Fitzhugh
Conditionally active antibody specialist Cytomx Therapeutics Inc. has agreed to work with Regeneron Pharmaceuticals Inc. to discover and develop new bispecific antibodies with what the partners said is the potential to "widen the therapeutic window and help minimize off-target effects."
Read More
View All Articles by Michael Fitzhugh

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 15, 2025
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing